NASDAQ: DNTH - Dianthus Therapeutics, Inc.

Yield per half year: -26.99%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Dianthus Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-09-12
ISIN US2528281080
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://dianthustx.com
Цена ао 18.27
Change price per day: +0.6039% (19.87)
Change price per week: +2.57% (19.49)
Change price per month: -3.01% (20.61)
Change price per 3 month: -12.09% (22.74)
Change price per half year: -26.99% (27.38)
Change price per year: -33.37% (30)
Change price per 3 year: +11 042.7% (0.1794)
Change price per 5 year: +2 489.71% (0.7719)
Change price per year to date: -17.63% (24.27)
All parameters

Underestimation

Title Value Grade
P/S 118.06 1
P/BV 2.09 7
P/E 0 0
EV/EBITDA -7.02 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -30.71 0
ROE, % -32.6 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0146 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 315.67 10
Yield Ebitda, % 32.81 5
Yield EPS, % -90.91 0
Total: 4.2
More

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Morningstar Small-Cap Growth ETF 0.01576 572.1 0.72598
iShares Morningstar Small-Cap ETF 0.00782 391.25 1.60498
0.01481.681.17



Head Job title Payment Year of birth
Mr. Marino Garcia M.B.A. President, CEO, Secretary & Director 1966 (59 years)
Mr. Ryan Savitz CFO and Chief Business Officer & Treasurer 1989 (36 years)
Mr. Simrat Randhawa M.B.A., M.D. Chief Medical Officer 1970 (55 years)
Mr. Edward G. Carr Chief Accounting Officer 1969 (56 years)
Mr. Judson Taylor Head of Technical Operations
Dr. Jeffrey Stavenhagen Ph.D. Chief Scientific Officer
Ms. Jennifer Davis Ruff VP and Head of Investor Relations & Corporate Affairs.
Mr. Adam M. Veness Esq. Senior VP, General Counsel & Secretary 1986 (39 years)
Ms. Kristina Maximenko Chief People Officer
Ms. Rashieda Gluck Head of Clinical Development Operations

Address: United States, New York, 7 Times Square - open in Google maps, open in Yandex maps
Website: https://dianthustx.com